A2AEME: Proteostasis Therapeutics
Proteostasis is planning to advance the combination in phase II development with the optimal dose as there was no plateau in ppFEV1 improvement at day 14. The company believes that longer duration studies are likely to increase ppFEV1 improvement from baseline. The company is anticipating phase III development to start in mid-2020.
Zahlen für Q1/19
- Umsatz 5 Mio. $
- Verlust 14 Mio. $
- Cash 105 Mio. $
- Cash-Reichweite ~5 Quartale
- MK 52 Mio. $
http://ir.proteostasis.com/news-releases/...st-quarter-2019-financial
https://www.benzinga.com/general/biotech/19/06/...-orphan-designation
https://www.nasdaq.com/de/symbol/pti/real-time
Proteostasis meldet Zahlen für Q2/19
- kein Umsatz
- Verlust 20 Mio. $
- Cash 88 Mio. $
- Cash-Reichweite ~4 Quartale
- MK 37 Mio. $
- neues 52 Wochen-Tief
http://ir.proteostasis.com/news-releases/...nd-quarter-2019-financial